GAITHERSBURG, Md., Nov. 8, 2010 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that the Company's management will participate in a panel discussion entitled, "The 2010 Gems in Wound Care Panel," hosted by Rodman and Renshaw, LLC on Thursday, November 11, 2010 at 4:30 p.m. Eastern time in Rodman and Renshaw's offices. The event will be moderated by Michael Higgins, Senior Specialty Pharmaceuticals Analyst, and Suraj Kalia, Senior Medical Devices Analyst at Rodman and Renshaw.
The topics to be covered will include the increase in the number of chronic wounds treated by physicians in hospitals and clinics, developing technologies and products used to address these issues, and innovative solutions that may be overlooked by investors in the space. Panel members will also discuss upcoming catalysts, challenges in obtaining approval for their pipeline products, and prospective Advanced Wound Care guidelines for clinical trial design.
Investors are welcome to attend in person. Please respond as space is limited. To attend, please RSVP to Jake Rynar at jrynar@rodm.com. This event also will be webcast live for RodmanTV registered users at http://rodm.tv/broadcast.php.
RodmanTV is a service for institutional investors and corporations that have a relationship with the firm. In addition, there will be conference call access (please contact your Rodman representative to get your dial-in number), and a replay of the discussion will be made available to Rodman and Renshaw subscribers at www.rodm.tv twenty-four hours after completion of the event.
About Cytomedix, Inc.
Cytomedix develops, sells and licenses regenerative biological therapies primarily for wound care, inflammation and angiogenesis. The Company markets the AutoloGel™ System, a device for the production of platelet rich plasma (PRP) gel derived from the patient's own blood for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for the separation of whole blood into red cells, platelet poor plasma (PPP) and PRP in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from PPP. The activAT® kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. The Company is pursuing a multi-faceted strategy to penetrate the chronic wound market with its products, as well as opportunities for the application of AutoloGel™ and PRP technology into other markets such as hair transplantation and orthopedics while actively seeking complementary products for the wound care market. Cytomedix also seeks to monetize other product candidates in its pipeline through strategic partnerships, out-licensing or sale. Most notably is its anti-inflammatory peptide (designated CT-112) that has shown promise in preclinical testing. Additional information regarding Cytomedix is available at www.cytomedix.com.
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, viability and effectiveness of the Company's sales approach and overall marketing strategies, the outcome of development or regulatory review of CT-112, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated, the Company's ability to successfully integrate the Angel® and activAT® product lines into its existing business, to assume and satisfy certain liabilities related to the Angel® and activAT® product lines, or its ability to service the deferred payments related to the acquisition of the Angel® and activAT® product lines. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.